Meta-analysis of smoking cessation medications on continuous abstinence rate at 1 year
Article Sidebar
Main Article Content
Abstract
Introduction: The aim of this study was to systematically review studies on smoking cessation medications and to conduct meta-analysis of efficacy of the first-line drugson continuous abstinence rate (CAR) at 1 year. Materials and Method: MEDLINE was searched from an inception to January 2015. Only studies using RCT design were selected. Primary outcome was a continuous abstinence at 1 year, confirmed by end-expiration carbon monoxide level ≤ 10 ppm or urinary cotinine level < 60 ng/ml. Results: Six studies of 4,456patients that passed selection criteria were included for the meta-analysis. All studies had high quality with Jadad score of 5. Varenicline and Bupropion contributed to a significantly higher CAR than placebo (OR, 2.56; 95% CI, 1.98-3.31 and OR, 1.86; 95% CI, 1.47-2.36, respectively). Comparing between the two drugs, Varenicline was more efficacious than Bupropion(OR,1.66; 95% CI,1.27-2.15). Conclusion: Our study confirmed the efficacy of both Varenicline and Bupropion over the placebo control and a higher efficacy of Vareniclinethan Bupropion in smoking cessation for one year.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Cahill K, Stevens S, Perera R, Lancaster T.Pharmacological interventions for smokingcessation: an overview and network meta-analysis(Review). Cochrane Database of Systematic Reviews 2013;5: CD009329.
Caraballo RS, Kruger J, Asman K, et al. Relapse among cigarette smokers: the CARDIA longitudinal study-1985-2011. Addict Behav 2014; 39(1): 106.
Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of Bupropion for smoking cessation in primary care. Arch Intern Med; 2007; 167(16):1791-7.
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, vssustained-release Bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 47-55.
Gonzales D, Jorenby DE, Brandon TH, Arteaga C, Lee TC. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with Varenicline, Bupropion SR or placebo. Addiction2010; 105(11): 2002-13.
Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the British household panel survey. NicotineTob Res 2010; 12: 1228-35.
Higgins JPT, Thomson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ2003;327: 557-60.
HughesJR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence Inclinical trials: issues and recommendations. Nicotine& Tobacco Research2003; 5, 13–25.
Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews2014; 1: CD000031.
Jadad R, Moore RA, Carrol D, et al. Assessing the quality of reportsof randomized clinical trails: Is blinding necessary? Control Clinical Trials1996; 17: 1-12.
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release Bupropion for smoking cessation: a randomized controlled trial. JAMA2006;296(1): 56-63.
Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of Varenicline, an alpha4beta2nicotinicacetylcholinereceptor partial agonist, in a12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. ClinTher2007; 29(6):1040-56.
Nides M, Oncken C, Gonzales D, et al. Smoking cessation with Varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and Bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166(15): 1561-8.
Piasecki TM. Relapse to smoking. Clinical Psychology Review2006; 26: 196–215.
Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of Bupropion SR for smoking cessation. J Intern Med2003;254(2):184-92.
Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull 1992; 111(1): 23-41.
Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addictive Behaviors2004; 29: 51-60.